Bristol-Myers Squibb Company (BMY) is a reputable global pharmaceutical company, headquartered in New York City, recognized for its relentless commitment to developing innovative healthcare solutions that contribute to bettering human health. The company is dedicated to discovering, developing, and delivering innovative medicines for patients with debilitating diseases requiring superior treatment.
Known by its ticker symbol BMY, Bristol-Myers Squibb was incorporated in 1887. Throughout the years, the company has established a name in the healthcare and pharmaceutical industry due to its passionate commitment to finding solutions to severe health conditions such as cancer, cardiovascular diseases, immunological diseases, and fibrotic diseases, among others.
The company has produced various established brands and pioneering drugs which have made significant contributions to the improvement of global health standards. It has developed a culture of excellence sustained by a productive workforce comprising over 30,000 employees, spread across multiple nations worldwide. BMY lays huge emphasis on research and development, investing billions annually to fuel ground-breaking medical discoveries and innovations.
Bristol-Myers Squibb also emphasizes social responsibility. It promotes the cause of affordable healthcare through various programs and initiatives. For instance, it endorses patient-support programs that help people access the medications they need, regardless of their financial situation.
BMY has had several successful mergers and acquisitions that have further empowered its resources and market stand. A notable one being the acquisition of Celgene Corporation in 2019, positioning BMY as a global biopharmaceutical leader.
Currently, it is on the Fortune 500 list for its annual revenue, making it one of the most promising pharmaceutical companies worldwide. Bristol-Myers Squibb remains a high-ranking player in drug manufacturing. It boasted a total revenue of $42.5 billion in 2020, with an impressive market cap around $141.4 billion.
However, like every pharmaceutical company, Bristol-Myers Squibb deals with intense competition, stringent regulatory burdens, and patent losses, which challenge its growth and dominance in the industry. Yet, despite these drawbacks, the company continues to achieve significant milestones in the pharmaceutical landscape.
Overall, Bristol-Myers Squibb is a testament to consistent and excellent performance. Its primary goal is to improve patients' lives through the discovery and development of innovative medicines. Its dedicated research, robust product portfolio, and strategic partnerships make it a vital contributor to the global healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Occidental Petroleum Corporation (NYSE:OXY) has declared a quarterly dividend of $0.28 per share, payable on January 15, 2027, to shareholders of record on December 10, 2026. This translates to an annualized dividend of $1.12 and a yield of 1.7%. The dividend is well-supported by earnings, with a current payout ratio of 35.4% and an anticipated future payout ratio of 21.8% based on analyst projections.
Miller Howard Investments Inc. NY has initiated a new $30.20 million position in The Home Depot, Inc. by acquiring 106,152 shares during the third quarter. Institutional investors now own 70.86% of the company, and Wall Street maintains a "Moderate Buy" rating with an average price target of $375.31. Home Depot also reported strong quarterly earnings of $4.92 EPS and $47.86 billion in revenue, along with a quarterly dividend of $2.33 per share.
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has received a "Moderate Buy" consensus rating from five analysts, with an average 12-month target price of $7.67. The company's stock opened at $1.82, with a market capitalization of $90.73 million, and reported a quarterly loss of $0.03 per share, surpassing the consensus estimate. Analysts anticipate a full-year loss of approximately $0.22 per share for the clinical-stage biotechnology company.
Gratus Wealth Advisors LLC recently acquired 16,313 shares of Starbucks Corporation, valued at approximately $1.53 million, in the third quarter. Institutional investors collectively own 72.29% of the company, and analysts generally rate Starbucks a "Moderate Buy" with an average price target of $110.14. Starbucks also reported strong quarterly earnings of $0.85 per share and increased its quarterly dividend.
Citizens Financial Group Inc. RI acquired 10,993 shares of NXP Semiconductors N.V. during the third quarter, a new stake valued at approximately $2.62 million. NXP Semiconductors recently reported strong quarterly earnings of $3.61 per share and revenue of $3.50 billion, exceeding analyst expectations. Analysts currently have a "Moderate Buy" rating for NXPI, with an average price target of $302.30.
Citizens Financial Group Inc. RI significantly increased its stake in Carrier Global Corporation (NYSE:CARR) during the third quarter, acquiring an additional 28,674 shares to bring its total holdings to 51,311 shares, valued at approximately $2.82 million. Carrier Global maintains a "Moderate Buy" consensus rating from analysts with an average target price of $70.43, significantly above its recent share price. The company exceeded earnings and revenue expectations in its last quarterly report and announced a quarterly dividend of $0.24 per share.
Davidson Kahn Capital Management LLC significantly reduced its stake in Floor & Decor Holdings, Inc. (NYSE:FND) by 56.7% in the third quarter, now holding 32,557 shares valued at $1.49 million. Other institutional investors also adjusted their positions, with some increasing and others acquiring new stakes in the company. Analysts currently have a consensus "Hold" rating on FND stock, with a target price of $56.50, following several price target adjustments and rating changes.
Evergreen Capital Management LLC has made a new $3.40 million investment in Linde PLC, purchasing 7,164 shares of the basic materials company. Institutional investors now collectively own 82.8% of Linde. The company also reported strong quarterly earnings, exceeding revenue and EPS estimates, and declared a $1.60 quarterly dividend.
Brookstone Capital Management acquired a new position in Best Buy Co., Inc. (NYSE:BBY) during the third quarter, purchasing 19,607 shares valued at approximately $1.73 million. Best Buy reported strong quarterly earnings of $1.47 per share, surpassing estimates, with revenue increasing by 3.6% year-over-year to $9.78 billion. The company also offers a quarterly dividend of $0.96, equating to an attractive 3.9% annual yield, while analysts maintain a consensus "Hold" rating with an average price target of $85.90.
Arnhold LLC recently acquired a significant stake in Element Solutions Inc. (NYSE:ESI), purchasing 481,907 shares valued at approximately $17.5 million during the third quarter. Element Solutions has shown strong financial performance, beating quarterly earnings expectations with $0.50 EPS and revenue of $995.3 million. Analysts generally maintain a "Buy" rating for the stock, with an average price target of $46.36, and the company also pays a quarterly dividend of $0.08 per share.